MAP PHARMACEUTICALS, INC. Research and Development Expense
MAP PHARMACEUTICALS, INC. reported Research and Development Expense of $7.86 million for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2012-11-06
- MAP PHARMACEUTICALS, INC. research and development expense for the quarter ending 2012-09-30 was $7.86M, a 16.80% increase year-over-year.
- MAP PHARMACEUTICALS, INC. research and development expense for the quarter ending 2012-06-30 was $7.77M, a 7.08% increase year-over-year.
- MAP PHARMACEUTICALS, INC. research and development expense for the quarter ending 2012-03-31 was $10.96M, a 5.24% decline year-over-year.
- MAP PHARMACEUTICALS, INC. research and development expense for the quarter ending 2011-12-31 was $8.11M, a 16.71% decline year-over-year.
- MAP PHARMACEUTICALS, INC. research and development expense for fiscal 2011 was $33.66M, a 10.89% decline from fiscal 2010.
- MAP PHARMACEUTICALS, INC. research and development expense for fiscal 2010 was $37.77M, a 21.30% decline from fiscal 2009.
- MAP PHARMACEUTICALS, INC. research and development expense for fiscal 2009 was $48.00M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 96 month | Research and Development Expense 99 month | Research and Development Expense 102 month | Research and Development Expense 105 month | Research and Development Expense 108 month | Research and Development Expense 111 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2012-09-30 | $7.86M 10-Q · filed 2012-11-06 | $15.63M derived: sum of 2 quarters · filed 2012-11-06 | $26.59M 10-Q · filed 2012-11-06 | $34.70M derived: sum of 4 quarters · filed 2012-11-06 | $277.72M 10-Q · filed 2012-11-06 | |||||
| 2012-06-30 | $7.77M 10-Q · filed 2012-07-27 | $18.73M 10-Q · filed 2012-07-27 | $26.85M derived: sum of 3 quarters · filed 2012-07-27 | $33.57M derived: sum of 4 quarters · filed 2012-11-06 | $269.87M 10-Q · filed 2012-07-27 | |||||
| 2012-03-31 | $10.96M 10-Q · filed 2012-05-08 | $19.07M derived: sum of 2 quarters · filed 2012-05-08 | $25.80M derived: sum of 3 quarters · filed 2012-11-06 | $33.06M derived: sum of 4 quarters · filed 2012-11-06 | $262.09M 10-Q · filed 2012-05-08 | |||||
| 2011-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $14.84M derived: sum of 2 quarters · filed 2012-11-06 | $22.09M derived: sum of 3 quarters · filed 2012-11-06 | $33.66M 10-K · filed 2012-03-30 | $251.13M 10-K · filed 2012-03-30 | |||||
| 2011-09-30 | $6.72M 10-Q · filed 2012-11-06 | $13.98M derived: sum of 2 quarters · filed 2012-11-06 | $25.55M 10-Q · filed 2012-11-06 | $35.29M derived: sum of 4 quarters · filed 2012-11-06 | $243.02M 10-Q/A · filed 2012-03-30 | |||||
| 2011-06-30 | $7.26M 10-Q · filed 2012-07-27 | $18.83M 10-Q · filed 2012-07-27 | $28.57M derived: sum of 3 quarters · filed 2012-07-27 | $38.57M derived: sum of 4 quarters · filed 2012-07-27 | $236.30M 10-Q/A · filed 2012-03-30 | |||||
| 2011-03-31 | $11.57M 10-Q · filed 2012-05-08 | $21.31M derived: sum of 2 quarters · filed 2012-05-08 | $31.32M derived: sum of 3 quarters · filed 2012-05-08 | $39.56M derived: sum of 4 quarters · filed 2012-05-08 | ||||||
| 2010-12-31 | $9.74M derived: 10-K 12 month − 10-Q/A 9 month · filed 2012-03-30 | $19.75M derived: sum of 2 quarters · filed 2012-03-30 | $27.99M derived: sum of 3 quarters · filed 2012-03-30 | $37.77M 10-K · filed 2012-03-30 | ||||||
| 2010-09-30 | $10.01M 10-Q/A · filed 2012-03-30 | $18.25M derived: sum of 2 quarters · filed 2012-03-30 | $28.04M 10-Q/A · filed 2012-03-30 | |||||||
| 2010-06-30 | $8.24M 10-Q/A · filed 2012-03-30 | $18.03M 10-Q/A · filed 2012-03-30 | ||||||||
| 2009-12-31 | $48.00M 10-K · filed 2012-03-30 |